

Amendment history:

- Corrigendum (January 2011)

Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies

Anneke I. den Hollander, Aaron Black, Jean Bennett, Frans P.M. Cremers

J Clin Invest. 2010;120(9):3042-3053. <https://doi.org/10.1172/JCI42258>.

Review

Nonsyndromic recessive retinal dystrophies cause severe visual impairment due to the death of photoreceptor and retinal pigment epithelium cells. These diseases until recently have been considered to be incurable. Molecular genetic studies in the last two decades have revealed the underlying molecular causes in approximately two-thirds of patients. The mammalian eye has been at the forefront of therapeutic trials based on gene augmentation in humans with an early-onset nonsyndromic recessive retinal dystrophy due to mutations in the retinal pigment epithelium-specific protein 65kDa (*RPE65*) gene. Tremendous challenges still lie ahead to extrapolate these studies to other retinal disease-causing genes, as human gene augmentation studies require testing in animal models for each individual gene and sufficiently large patient cohorts for clinical trials remain to be identified through cost-effective mutation screening protocols.

Find the latest version:

<https://jci.me/42258/pdf>





Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies

Anneke I. den Hollander,^{1,2} Aaron Black,³ Jean Bennett,³ and Frans P.M. Cremers^{2,4}

¹Department of Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. ²Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, Netherlands. ³Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

⁴Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.

Nonsyndromic recessive retinal dystrophies cause severe visual impairment due to the death of photoreceptor and retinal pigment epithelium cells. These diseases until recently have been considered to be incurable. Molecular genetic studies in the last two decades have revealed the underlying molecular causes in approximately two-thirds of patients. The mammalian eye has been at the forefront of therapeutic trials based on gene augmentation in humans with an early-onset nonsyndromic recessive retinal dystrophy due to mutations in the retinal pigment epithelium-specific protein 65kDa (RPE65) gene. Tremendous challenges still lie ahead to extrapolate these studies to other retinal disease-causing genes, as human gene augmentation studies require testing in animal models for each individual gene and sufficiently large patient cohorts for clinical trials remain to be identified through cost-effective mutation screening protocols.

Introduction

Vision is considered by many to be the most important of the five senses. Visual perception is mediated by the retina, the light-sensitive tissue that lines the inner surface of the eye (Figure 1). Light striking the retina initiates a cascade of events that ultimately triggers nerve impulses to the brain (Figure 2). The retina is a complex, layered structure consisting of neuronal and supporting cells. The photoreceptor cells are the light-sensitive cells that absorb light from the field of view and, through the phototransduction cascade, convert this information into a change in membrane potential. There are two types of photoreceptors: rods and cones. Rods mediate vision in dim light, while cones support daytime vision and the perception of color. Cones are concentrated in the central part of the retina, which is known as the macula, and the highest cone density is found in the center of the macula (an area known as the fovea), which enables high-acuity vision. The retinal pigment epithelium (RPE) supports and nourishes the photoreceptor cells and is firmly attached to the underlying vascular layer, which is known as the choroid. The RPE mediates the visual cycle, a continuous process by which the retinoids used in the phototransduction cascade are recycled.

Retinal dystrophies are characterized by degeneration of photoreceptor and RPE cells; they represent the major cause of incurable familial blindness in the Western world. The inheritance pattern of the diseases can be autosomal recessive (AR), autosomal dominant (AD), or X-linked (XL). Retinal dystrophies are generally classified based on whether the disease primarily affects the rods or the cones (and thus predominantly affects the macular or the peripheral retina) (Table 1) (1). These diseases show substantial clinical and genetic overlap (Figure 3). The distinction between some retinal dystrophies can be very subtle or even arbitrary, and mutation of a

single gene can result in varied clinical diagnoses (Table 1). In addition, there is a plethora of syndromes (e.g., Bardet-Biedl syndrome, Joubert syndrome, Senior-Loken syndrome, and Usher syndrome) in which retinal abnormalities are consistently or frequently found (1, 2). These syndromes are not the topic of this Review; rather, we focus on retinal dystrophies that occur in the absence of concomitant dysfunction of other organs (i.e., nonsyndromic retinal dystrophies, in particular the AR and XL forms).


During the past few years, exciting progress has been made in developing gene augmentation therapies to correct the genetic defects causing nonsyndromic retinal dystrophies. A prerequisite for this type of therapy is that the underlying genetic defect in patients is known. In this Review, we discuss the progress that has been made toward understanding the genetic basis of AR and XL nonsyndromic retinal dystrophies. We also provide an overview of animal models of these diseases and discuss the challenges in developing successful retinal gene augmentation therapies.

Phenotypes of inherited nonsyndromic retinal diseases

Generalized and/or peripheral retinal dystrophies. Retinitis pigmentosa (RP) represents the most frequent cause of inherited visual impairment, with a worldwide prevalence of 1:4,000 (1). It encompasses a clinically heterogeneous group of progressive disorders that primarily affect the function of the photoreceptors and the RPE (2). There is a large variability in the age of onset, progression, retinal appearance, and final visual outcome. Pigment granules from the RPE migrate to perivascular sites of the neural retina secondary to photoreceptor death, forming the hallmark “bone spicules” (Figure 1C). The attenuation of the retinal arterioles and veins probably also represents a secondary effect of photoreceptor cell death. Initially, rods are predominantly affected, resulting in night blindness and tunnel vision. Later in the disease process, cones also are affected, which can result in complete blindness (1). Thirty percent of RP patients show AR inheritance, 20% show AD inheritance, and 10% show XL inheritance (2). Approximately 40% of RP patients represent isolated cases.

Conflict of interest: Jean Bennett is a co-inventor on the pending patent “A Method of Treating or Retarding the Development of Blindness” but waived any financial interest in this technology in 2002. Jean Bennett presented a seminar at Novartis in 2009.

Citation for this article: *J Clin Invest.* 2010;120(9):3042–3053. doi:10.1172/JCI42258.

**Figure 1**

Anatomy of the human eye and retina. (A) Cross section showing the major landmarks of the human eye and retina. The borders of the macula, which is adjacent to the optic disc, are indicated with a dashed line. Fundus views of patients with (B) normal vision; (C) retinitis pigmentosa (pigmentary changes indicated by arrowheads); (D) STGD1 due to *ABCA4* mutations; and (E) LCA due to a homozygous *RPE65* mutation. +, fovea; od, optic disc; INL, inner nuclear layer; ONL, outer nuclear layer.


Patients with Leber congenital amaurosis (LCA) are severely visually impaired or blind from birth. They present with nystagmus and a retinal appearance that varies from normal to mild pigment mottling with mild vascular attenuation to severe pigmentation and vascular attenuation that resemble those of the fundus in RP-like dystrophy (1) (Figure 1, C-E). A nondetectable electroretinogram (ERG) in the first year of life is pathognomonic. Some patients show a rod-cone degeneration pattern and others a cone-rod degeneration pattern. Almost all LCA patients show AR inheritance, with a worldwide incidence of approximately 1:30,000 (2).

Retinal dystrophies primarily affecting the macula. Stargardt disease type 1 (STGD1) (OMIM #248200; see Table 1 for additional listings) is the most common juvenile macular dystrophy, with a worldwide prevalence of 1:10,000 (3). STGD1 in most cases is characterized by visual acuity loss in early childhood or early adolescence, but it can also appear later in life. Macular atrophy can develop and is often characterized as having a beaten bronze appearance or a bull's-eye pattern (Figure 1D). Fundus flavimaculatus is a phenotypic variant with yellow flecks associated with secondary macular atrophy.

In the majority of patients, the accumulation of lipofuscin, which is composed of a mixture of lipids, proteins, and different fluorescent compounds, results in progressive retinal/macu-

lar changes that include alterations in fundus autofluorescence (4). Patients with AR cone-rod dystrophy (CRD) initially have a predominant loss of cone function. They show photoaversion (a preference to avoid light) and defective color vision in adolescence and early adult life, followed by decreased central vision due to progressive CRD. The macula may show a bull's-eye appearance; there are islands of impaired visual acuity and subsequently large paracentral scotomas (blind spots). Bone spicules generally are absent, and the retinal vessels show mild thinning.

Impairment or death of the cone photoreceptor cells is the clinical hallmark of cone disorders, which have an estimated prevalence of 1:35,000 (5). Achromatopsia (ACHM) is a stationary congenital AR cone disorder that is characterized by low visual acuity, photophobia, nystagmus, severe color vision defects, diminished cone ERG responses, and normal rod ERG responses. The literal meaning of ACHM (absence of color vision) does not fully capture the clinical picture, as ACHM patients generally show more severe visual acuity defects than, for example, patients with cone dystrophy (CD) in the early stage of disease (6). CD is a progressive cone disorder in which patients may initially have normal cone function but a pale optic disc predominant in the temporal side. They develop progressive loss of visual acuity, increasing photophobia, color vision disturbances, and diminished cone responses

**Figure 2**

Schematic representation of three major processes in human rod photoreceptor cells and the RPE. Upper panel: The retinoid cycle taking place in rod photoreceptor cells (PC) and the RPE. Upon photactivation, 11-cis-retinal is converted into all-trans-retinal and dissociates from activated rhodopsin. The all-trans-retinal is then recycled to produce more 11-cis-retinal via several enzymatic steps in the RPE. ABCA4 mediates transport of all-trans-retinal to the outside of the photoreceptor outer segment disks. The localization and function of proteins involved in AR and XL nonsyndromic retinal dystrophies are depicted, with the exception of GCAP, a critical Ca²⁺-binding interactor of GUCY2D, which is mutated in autosomal dominant CRD (<http://www.sph.uth.tmc.edu/Retnet/home.htm>). CRALBP, protein product of *RLBP1*; IRBP, protein product of *RBP3*; RAL, retinal; RE, retinyl esters; RHO^a, photoactivated rhodopsin; ROL, retinol. Middle panel: The phototransduction cascade in rod PCs. Upon photoactivation, amplification of the signal is mediated through the α-subunit of transducin and phosphodiesterase, which results in closure of the cGMP-gated channel, hyperpolarization of the cell, and reduced glutamate release at the synapse. SAG, arrestin. Lower panel: Ciliary transport along the connecting cilium. Kinesin II family motors mediate transport toward the outer segments; cytoplasmic dynein 2/1b (DYNC2H1) is involved in transport processes from the outer segments toward the inner segments. The precise roles of CEP290, Lebercilin, RPGR, RPGRIP1, and RP1 in ciliary transport processes are not yet known. AIPL1 (not indicated in this figure) is a chaperone for proteins that are farnesylated. For IDH3B and PRCD, the exact cellular functions are not known. ADAM9, MERTK, and RGR are secreted by the RPE and localize in the interphotoreceptor matrix. The *CNGA3*, *CNGB3*, *GNAT2*, and *PDE6C* genes are specifically expressed in cone PCs and therefore not indicated in this figure. At the right side, a Müller cell (MC) connects to the photoreceptor cell with the transmembrane protein CRB1. Usherin, protein product of *USH2A*.

on ERG, usually in the first or second decade of life. The visual acuity of these patients generally worsens to legal blindness before the fourth decade of life (5).

Molecular genetics of retinal dystrophies

Genetic heterogeneity. A striking characteristic of nonsyndromic AR and XL retinal dystrophies is their genetic heterogeneity (Figure 4 and Table 1). The exception is STGD1, which in nearly all cases is caused by mutations in the ATP-binding cassette, subfamily A, member 4 (*ABCA4*) gene (7). Approximately 70% of patients with

recessive XL RP carry mutations in the retinitis pigmentosa GTPase regulator (*RPGR*) gene, and a small percentage carry mutations in the retinitis pigmentosa 2 (*RP2*) gene (8). The most extreme example of genetic heterogeneity is AR RP, with mutations in at least 25 genes identified to cause the condition to date, none of which is mutated in a large fraction of patients (Retnet: <http://www.sph.uth.tmc.edu/RetNet/>). To date, 14 genes have been linked to AR LCA, 6 genes to AR CD, 4 genes to AR CRD, and 4 genes to ACHM (Figure 4) (9). It is estimated that the identified genes account for approximately 50% of AR RP, 70% of AR LCA, 40% of AR CRD,

**Table 1**

Nonsyndromic recessive retinal dystrophy genes, their associated human phenotypes, animal models, and gene therapy studies

Human gene	Recessive phenotypes	Cellular expression in the retina	Mouse model (variant)	Other recessive animal models (variant ^A)	Gene refs.	OMIM no. (gene)	OMIM no. (disease)	Gene therapy model	Gene therapy refs.
<i>ABCA4</i>	STGD1, CRD, RP	Cones and rods	KO	No	73	601691	248200, 604116, 601718	Mouse	40, 49
<i>ADAM9</i>	CRD	RPE	KO	No	74	602713	612775	No	
<i>AIPL1</i>	LCA	Rods	KO, KD	No	75–77	604392	604393	Mouse	32, 72
<i>CACNA2D4</i>	CD	Unknown	C57BL/10 (c.2367insC)	No	78	608171	610478	No	
<i>CEP290</i>	LCA, RP	Cones and rods	rd16 (Δex35–39)	Cat (c.6960+9T→G)	79, 80	610142	611755	No	
<i>CERKL</i>	CRD, RP	Cones and rods	KO	No	81	608381	608630, 268000	No	
<i>CNGA1</i>	RP	Rods	No ^B	No		123825	612095	No	
<i>CNGA3</i>	ACHM, CD	Cones	KO	No	82	216900	268000	No	
<i>CNGB1</i>	RP	Rods	KO	No	83, 84	600724	600724	No	
<i>CNGB3</i>	ACHM, CRD	Cones	KO	Dog	85, 86	605080	262300	Mouse	87
<i>CRB1</i>	LCA, RP	Müller cells	KO, KI (p.C249W), rd8	No	88–90	604210	600105	No	
<i>CRX</i>	LCA	Cones and rods, bipolar cells	KO	No	91	602225	120970, 268000	No	
<i>EYS</i>	RP, CRD	Cones and rods	No mouse ortholog	No		612424	602772	No	
<i>GNAT2</i>	ACHM	Cones	Cpf13 (p.D200N)	No	92	139340	139340	Mouse	93
<i>GUCY2D</i>	LCA	Cones and rods	KO	rd chicken (Δex4–7)	94, 95	600179	204000	Mouse	23, 96
<i>IDH3B</i>	RP	Unknown	No	No	97, 98	604526	612572	No	
<i>KCNV2</i>	CD	Cones and rods	No	No	99–101	607604	610024	No	
<i>LCA5</i>	LCA	Cones and rods	No ^B	No	102	611408	604537	No	
<i>LRAT</i>	LCA, RP	RPE	KO	No	103	604863	613341	Mouse	104
<i>MERTK</i>	LCA, RP	RPE	KO	RCS rat	105	604705	604705	Rat	106, 107
<i>NR2E3</i>	RP, ESCS	Rods	KO, rd7	No	108	604485	268100, 604485, 611131	No	
<i>NRL</i>	RP	Rods	KO	No	109	162080	162080	No	
<i>PDE6A</i>	RP	Rods	Chemically induced	rcd3 dog	104, 110	180071	180071	No	
<i>PDE6B</i>	RP	Rods	rd1, rd10	Dog	111, 112	180072	180072	Mouse	41, 56, 113–116
<i>PDE6C</i>	ACHM, CD	Cones	cpf1	No	117–119	600827	600827, 613093	No	
<i>PRCD</i>	RP	Cones and rods, RPE, GCL	No	Dog	120, 121	610598	610599	No	
<i>PROM1</i>	RP	Cones and rods	KO	No	122	604365	612095	No	
<i>RBP3</i>	RP	Cones, rods, RPE, Müller	KO	No	123, 124	180290	NA	No	
<i>RD3</i>	LCA	Cones and rods	rd3	No		180040	610612	No	
<i>RDH12</i>	LCA	Rods	KO	No	125–128	608830	612712	No	
<i>RDH5</i>	CD	RPE	KO	No	129, 130	601617	601617	No	
<i>RGR</i>	RP	RPE	KO	No	131, 132	600342	600342	No	
<i>RHO</i>	RP	Rods	KI, KO	No		180380	180380, 184380	Mouse	133
<i>RLBP1</i>	RP, RPA	RPE, Müller	KO	No		180090	1800990, 607476	No	
<i>RP1</i>	RP	Cones and rods	KO	No	134, 135	603937	180100	No	
<i>RP2</i>	XL RP	Ubiquitous	No ^B	No	136, 137	300757	312600	No	
<i>RPE65</i>	LCA, RP	RPE	KO, KI (p.R91W), rd12	Dog	97, 98	180069	204100	Mouse, dog	34, 36, 57, 138–140
<i>RPGR</i>	XL RP, XL CRD	Cones and rods	KO	XLPR1A1, A2 dogs	99–101	312610	300029, 304020, 300455	No	
<i>RPGRIP1</i>	LCA, CRD	Cones and rods	KO	Dog	102	605446	605446, 608194	Mouse	141
<i>SAG</i>	RP	Rods	No ^B	No	103	181031	181031	No	
<i>SPATA7</i>	LCA, RP	GCL, INL, PR	No ^B	No	105	609868	609868, 604232	No	
<i>TULP1</i>	LCA, RP	Cones and rods	KO	No	108	602280	602280	No	
<i>USH2A</i>	RP, USH2	Cones and rods, OPL	KO, RBF/DnJ	No	109	608400	608400	No	

^AVariants listed only if they are not null alleles. ^BES cells available at EUCOMM (<http://www.eucomm.org/>) or KOMP (<http://www.komp.org/>). OMIM: <http://www.ncbi.nlm.nih.gov/omim>; ECSC, enhanced S syndrome; KD, knockdown; KI, knock-in; NA, not available.




Figure 3

Phenotypic overlap among autosomal recessive retinal dystrophies. Patients with ACHM display a virtually stationary cone defect in which cones are principally defective. At end stage, CD can hardly be distinguished from CRD. Patients with STGD1 later in life show mid-peripheral defects similar to those in CRD patients. Patients with RP initially display tunnel vision due to rod defects that very often progresses to complete blindness when the cones are also affected. In patients with LCA, the defects can occur in both types of photoreceptors, or in RPE cells, and therefore clinical and molecular genetic overlap with CD, CRD, or RP can be expected.

10% of AR CD, and 80% of ACHM (9). Additional molecular genetic research is therefore warranted to identify the remaining causes of these diseases. This is important if gene augmentation therapies (such as that described below in “Gene augmentation therapy in the clinic” for LCA due to *RPE65* mutations), which are gene specific, are to be developed.

Several genes cause distinct or partially overlapping clinical phenotypes. For example, mutations in *ABCA4* cause STGD1, are a major cause of AR CRD, and are an infrequent cause of an RP-like dystrophy (10, 11). Mutations in the genes encoding crumbs homolog 1 (*CRB1*), lecithin-retinol acyltransferase (*LRAT*), MER receptor tyrosine kinase (*MERTK*), *RPE65*, spermatogenesis-associated protein 7 (*SPATA7*), and Tubby-like protein 1 (*TULP1*) can cause both LCA and juvenile-onset RP (2, 12).

The genes identified in nonsyndromic AR and XL retinal dystrophies affect a wide variety of molecular pathways and processes. In Figure 2, we depict three important processes that are affected in these conditions: the rod phototransduction cascade, the retinoid cycle, and ciliary transport (refs. 2, 9, and refs. therein).

Molecular diagnostics. Genetic testing of patients with nonsyndromic AR and XL retinal dystrophies is performed for genetic counseling purposes, that is, to estimate the recurrence risk for future offspring, and to confirm preliminary clinical diagnoses, which can be challenging in all stages of these diseases. Establishing a definite molecular diagnosis aids in the planning for clinical follow-up and allows a more accurate disease prognosis. With the advent of gene therapy and other types of treatment, the identification of a patient’s gene mutation(s) is becoming increasingly important. Mutation identification not only presents technologic and economic challenges because of the enormous allelic and genetic heterogeneity displayed by the inherited retinal dystrophies, but also requires a well-balanced program to raise awareness among patients, health insurance companies, and the general public.

As discussed above (see *Genetic heterogeneity*), the genes responsible for approximately 65% of the inherited AR retinal dystrophies are currently known (2, 9). The challenge is to translate this enormous body of scientific knowledge into clinical practice, as even

in the Western world, fewer than 10% of patients with inherited blindness know their genetic defect. Which techniques can be used to cost-effectively identify the underlying genetic defects?

Conventional Sanger sequencing of relatively frequently occurring variants is warranted for the centrosomal protein 290kDa (*CEP290*) c.2991+1655A→G mutation that is found in 20% of LCA patients of European descent (13), and the cyclic nucleotide gated channel β3 (*CNGB3*) p.T383fsX variant that is found in 50% of ACHM patients (14). Sanger sequencing is also preferred for diseases for which the majority of mutations can be found in one or a few genes encompassing a maximum of approximately 50 exons/amplicons, such as ACHM (caused by mutations in the 18-exon *CNGB3* gene or the 8-exon cyclic nucleotide gated channel α3 [*CNGA3*] gene), STGD1 (caused by mutations in the 50-exon *ABCA4* gene), and XL RP (caused by mutations in the 19-exon *RPGR* gene or the 5-exon *RP2* gene).


Analysis of all known LCA mutations can be performed cost-effectively using allele-specific primer extension analysis (15), which yields pathologic variants in approximately 60% of patients. This technique is available but less cost effective for AR CRD and AR RP, for which 25%–35% of alleles are known (16).

Next-generation sequencing represents a major breakthrough in cost-effective sequencing (17). The cost per base pair for this technology compared with conventional Sanger sequencing has dropped 100- to 1,000-fold. To identify novel retinal disease genes, all the exons from a sizable genomic region (e.g., established via linkage analysis [ref. 18] or by identity-by-descent mapping) can be sequenced. Alternatively, all exons of the human genome (the exome) can be sequenced for less than \$10,000. Studies are in progress to tailor next-generation sequencing technology for diagnostic purposes, for example, to sequence the exons of all (approximately 180) human retinal disease genes, or a subset of these genes, for less than \$1,000.

With the identification of numerous variants in many putative disease genes, it will be a challenge to discriminate pathologic from benign sequence variants. In addition, nonsyndromic retinal dystrophies in a subset of patients may be caused by the cumulative effect of mutations in more than one gene, and detailed knowledge about the interactions of proteins in networks (such as at the connecting cilium) will be required to begin to understand genetic interactions.

Animal models for recessive retinal dystrophies

Mouse models. Rodent models of retinal dystrophy have been very useful for proof of concept of gene therapy studies, in part because the degeneration process (like the lifespan of these animals) is often condensed into weeks or months. Thus, the effects of a given approach can be evaluated fairly quickly in a large number of animals. Pathologic effects of various genes/mutations can also be evaluated in these models. The primary disadvantage of mouse models of retinal dystrophies is that the mouse differs from the human in that it lacks the cone-dominated central region of the posterior fundus. Additionally, the size and anatomy of the mouse eye differ substantially from those of the human eye, thereby requiring different surgical approaches for gene delivery. Further, the lifespan of the mouse is short, which, in some cases, may limit the relevance of the model. In Table 1 we list the 44 currently known genes underlying nonsyndromic recessive retinal dystrophies in human. Mouse orthologs are known for each of these genes, except eyes shut homolog (*EYS*) (19). Naturally occurring or man-made

**Figure 4**

Prevalence of mutations in genes causing genetically heterogeneous retinal dystrophies. Estimated prevalence of mutations in genes causing AR RP, LCA, AR CRD, AR CD, and ACHM. Mutations in approximately 50% of AR RP, 30% of LCA, 60% of AR CRD, 90% of AR CD, and 20% of ACHM remain to be identified. For several genes, only one or a few families with mutations have been reported; in these cases, the gene frequency was estimated to be 1%. Estimates are based on literature searches (<http://www.sph.uth.tmc.edu/Retnet/home.htm>) and our own experience.

mouse models are already available for 35 of these genes, including 27 knockouts, 3 knock-ins, 1 knockdown, and 11 spontaneous mouse models (Table 1). Spontaneous models are common because blindness does not generally affect longevity or fertility (20).

In addition to the existing mouse models, large-scale research initiatives in the United States (KnockOut Mouse Project [KOMP], <http://www.komp.org/>; and Lexicon Pharmaceuticals, <http://www.lexicongenetics.com>), Canada (North American Conditional Mouse Mutagenesis Project [NorCOMM], <http://www.norcomm.org/>), and Europe (European Conditional Mouse Mutagenesis Program [EUCOMM], <http://www.eucomm.org/>) are developing and distributing mouse ES cell lines and mice carrying gene-trap or -targeted mutations across the mouse genome. As a result of these initiatives, it is now possible to obtain mouse ES cell lines lacking one of five AR nonsyndromic retinal dystrophy genes mentioned in Table 1 for which there are currently no mouse models available: mouse ES cell lines lacking *CNGA1* and *SPATA7* are available from KOMP, while mouse ES cell lines lacking LCA type 5 (*LCA5*), *RP2*, and S-arrestin (*SAG*) are available from EUCOMM. Additional mouse models are expected to become available or can be requested to enter the pipeline as these large-scale projects progress.

Large animal models. Several large animal models of AR retinal dystrophies are also available. Many of these have been identified through evaluation of visual dysfunction in family pets, and others have been identified in screens prior to training guide dogs. Some of these, such as a Briard dog with a null mutation in *RPE65* that models LCA caused by *RPE65* mutations, are enrolled in gene augmentation studies. Others may be used in future studies (e.g., a mutant Abyssinian cat with congenital blindness due to a *CEP290* splice defect and a mutant Irish setter dog with AR RP due to a *PDE6B* mutation) (Table 1). It should be noted that in all three of these models, the gene defects causing disease were not identified until the gene defect had been identified in humans. In fact, in one of these models, the Briard dog, the disease had been originally misdiagnosed as congenital stationary night blindness (21), and the diagnosis was changed to LCA after the human mutation was identified.

The retinas of dogs and cats are more anatomically similar to those of humans than are the retinas of mice. While only primates have maculas, dogs and cats have a cone photoreceptor-enriched area, the area centralis, which is functionally similar to the macula. The size of their eyes is also similar to that of humans, so that surgical approaches that would be acceptable in humans can be used. In contrast, aside from the fact that it is small, surgery in the mouse eye is difficult due to the fact that the lens occupies almost the entire vitreous cavity (Figure 5A). Thus, subretinal injections in the mouse are usually carried out through a posterior approach (Figure 5A), whereas they can be carried out under direct visualization in dogs, cats, and other large animals (Figure 5, B and D–G).




Figure 5

Approaches for surgical delivery of gene therapy vectors in retinal disease. Subretinal injection is necessary to place the gene augmentation therapy reagent in contact with the target photoreceptor and RPE cells. Arrows indicate the approaches used in the postnatal/adult mouse (A), large animals/humans (B), and fetal mice (C; injection into the subretinal space adjacent to retinal progenitor cells). (D–G) Frames from an intraoperative video taken during subretinal injection of the macula in a human with rAAV2.hRPE65v2 (64). In G, the cannula is withdrawn, revealing the raised fovea (black arrowhead). *optic disc; white arrowheads indicate edge of the expanding detachment.

Finally, nontraditional animal models have been identified that provide additional interesting data with respect to disease pathogenesis and approaches to therapy. The rd (guanylate cyclase 2d^{-/-} [Gucy2D^{-/-}]) chicken was first identified in a flock of Rhode Island Red chickens because it could not see well enough to find its food (22). This model was used successfully to demonstrate efficacy using *in ovo* gene transfer. The retinal and visual function improvements after gene augmentations therapy in this model provide compelling evidence that this approach could be effective in humans (23).

Gene augmentation therapy considerations

With recent progress in delineating the molecular genetic bases of nonsyndromic AR and XL retinal dystrophies in humans and animals, it is logical to ask how we can use this information to correct the diseases. Gene augmentation strategies have been tested successfully now in a dozen different animal models (Table 1). Since DNA is not able to pass through cell membranes efficiently, it is delivered through a delivery agent (vector). There are a number of details that affect the success of retinal gene augmentation, including selection of the appropriate vector and delivery method. Variables relevant to vector selection include tropism, cargo capacity, stability of expression, and/or immunogenicity.

Vector selection: viral vectors. There are a number of nonviral and viral vectors that have been used successfully in retinal gene therapy proof-of-concept studies (24, 25). Methods of nonviral delivery include the use of liposomes and DNA condensation reagents as vectors as well as electroporation, iontophoresis, and high-velocity cell bombardment (“gene gun”). Advantages of such physico-chemical approaches include the fact that there are no size limitations with respect to the transgene cassette and that the approach does not deliver additional antigens besides the DNA/DNA-binding

reagents themselves. Potential disadvantages include concern about longevity of expression and efficiency of nuclear entry, although a recent report using compacted DNA nanoparticles showed evidence of marked physiologic rescue for at least 30 days after delivery (26).

Viral vectors, such as recombinant adenovirus (rAd; both early-generation and helper-dependant viruses), recombinant adeno-associated virus (rAAV), and lentivirus, have been tested extensively *in vivo* in the retina in safety and proof-of-concept studies. Improvements in vector design, including modification to capsids, envelopes, and surface proteins, have provided an expanded toolkit for achieving the desired transduction parameters. Although the cargo capacity of rAAVs (4.8 kb) is smaller than that of early-generation rAd or lentivirus vectors (approximately 7 kb), rAAVs generally target photoreceptors more efficiently than those vectors. Because of this and also because of the seemingly benign immune responses that it triggers, it has been used in more preclinical studies than the other vectors. Further, with the identification of scores of naturally occurring AAV variants and with the development of technology to modify the AAV capsid, a num-

ber of rAAVs are available that can deliver transgenes efficiently to a variety of different retinal cell types (27, 28). These vectors differ markedly in their cellular specificity, efficiency of transduction, and onset of transgene expression. While rAAV serotype 2 (rAAV2) vectors target RPE cells efficiently (and photoreceptors less efficiently), it takes up to 6 weeks for transgene expression mediated by this vector to plateau (29). In comparison, rAAV5 and rAAV8 vectors transduce photoreceptors with much higher efficiency than rAAV2 and result in transgene expression within 5–10 days after delivery (30, 31). It is thus not surprising that rAAV2 vectors perform well in delivering a therapeutic transgene to RPE cells in animals and humans with a relatively slowly progressing retinal degenerative disease (LCA due to *RPE65* mutations; Table 1) but an rAAV5 or -8 vector is required to target photoreceptors in an animal model with a much faster rate of retinal degeneration (e.g., RP or LCA due to aryl hydrocarbon receptor-interacting protein-like 1 [AIPL1] mutations; Table 1 and ref. 32). The expression time courses are affected by the time necessary for the single-stranded AAV genome to become a transcriptionally competent double-stranded form, and the time to reach peak expression levels can be reduced by selection of self-complementary (double-stranded) AAV. There are, however, limitations with the cargo capacity of self-complementary rAAV (33). Nevertheless, regardless of the capsid serotype or structure of the transgene cassette, rAAV-mediated retinal gene transfer results in stable transgene expression in target retinal cells (34), even though rAAV-delivered transgenes are maintained in an episomal fashion (35).

Similar to rAAV, lentivirus and rAd are generally tropic for the RPE and have therefore been effective in animal models of RPE disease. These include spontaneous null mutation mouse and dog models of LCA due to *RPE65* mutations and a spontaneous null rat model of AR RP due to *MERTK* mutations (Table 1)



(34, 36, 37). However, by swapping the envelope or genome (e.g., using an equine-derived versus a human-derived lentivirus vector) or pseudotyping with different fiber proteins (e.g., using a rAd containing an envelope fiber from an Ad37 type rAd instead of an Ad5-based vector; refs. 38, 39), photoreceptor transduction can be enhanced. These modified vectors have been used with some success in animal models of primary photoreceptor disease such as STGD1 (lentivirus) or AR RP caused by *PDE6B* mutations (rAd) (40, 41). Lentiviruses are integrating vectors and thus mediate stable transgene expression (assuming the appropriate promoter is used), although there is a risk of insertional mutagenesis (42). Adenoviruses are not integrating, and expression does not persist for more than a couple of months (43). This may be due, at least in part, to immune clearance, as early-generation rAd vectors carry viral open reading frames that encode immunogenic viral proteins (44). Adenovirus vector epitopes are major factors in triggering the host immune response, which can include the generation of neutralizing antibodies as well as activation of a CD8⁺ CTL response (45). The latter is associated with release of cytokines that activate macrophages that can then phagocytose target cells. CTLs and other cytotoxic cells (such as NK cells) also directly kill virus-infected cells. Such responses can lead to systemic inflammatory response syndrome and death after systemic administration (46). The responses in animals after intraocular exposure of early-generation rAd vectors are much more benign, perhaps due to the unique immune environment of the eye, but they do limit stability of transgene expression (43) (reviewed in ref. 47). Helper-dependent adenoviruses, vectors deleted of all open reading sequences, are likely to lead to safe and stable demonstration of proof of concept of gene therapy in the eye.

Cargo capacity is generally not an issue with lentivirus vectors and first-generation rAd vectors, both of which can accommodate approximately 8 kb, but the cargo capacity of rAAV vectors (4.8 kb) can be challenging for large photoreceptor-specific cDNAs such as *ABCA4*, *CEP290*, myosin VIIA (*MYO7A*), and usher syndrome type-2A protein (*USH2A*) (48). It was thought that rAAV2/5 vectors could deliver the intact 7.8-kb *ABCA4* cDNA (49). However, subsequent analyses have shown that only a small portion of rAAVs package the intact cassette (J. Bennicelli, J.F. Wright, and J. Bennett, unpublished observations) and most of them contain partial cassettes after gene augmentation therapy in mice (J. Bennicelli, J.F. Wright, and J. Bennett, unpublished observations). It is possible that, after infection of the cell, homologous recombination between sequences in these partial cassettes allows production of the full-length *ABCA4* protein. Multiple groups have proposed such a mechanism for delivery of other large cDNAs by AAV (50, 51) and suggest that for large cDNA targets, it might be possible to use two or three rAAVs that carry different portions of the large transgene cassette that recombine in the target cell to produce the full-length transgenic protein.

Alternative strategies to packaging large transgene cassettes into rAAVs include delivery of a cDNA encoding a truncated but functional protein, supply of ribonucleotides (antisense oligonucleotides) that could modulate gene expression through interference with RNA processing (as described by van Deutekom and coworkers for the severe muscular dystrophy Duchenne muscular dystrophy; ref. 52), and delivery of the cDNA in segments through a “*trans-splicing*” approach. For the latter approach, the cDNA is split into two separate rAAV vectors using an engineered intron to mediate splicing of the two cDNA segments within the cell.

Feasibility of this approach using a small transgene cassette has been demonstrated *in vivo* in the mouse retina (53). In that study, a cytomegalovirus-promoted *lacZ* cDNA was split in half, and an intron splice donor sequence was placed on the 5' half. A splice acceptor was placed on the 3' half of the cDNA. The two pieces of the cassette were then packaged separately in AAV. Coinfection of cells *in vitro* and *in vivo* in the eye with the resultant AAVs resulted in transgene expression, whereas infection with either one of the AAVs alone did not (54).

Additional delivery challenges. Challenges relevant to the surgical delivery of the appropriate vectors are largely solvable. Importantly, the transgene should be delivered within the appropriate time frame – before degeneration has progressed to the point of eliminating the target cells (Figure 5G). In some AR and XL nonsyndromic retinal dystrophies, such as LCA due to *RPE65* mutations, there is a large window in which to correct the disease. Even in that disease, however, beyond a particular stage, there are no cells remaining that can be rejuvenated. In others, the disease initiates and thus must be corrected, very early in life (i.e., it has a developmental component). An example of a disease in which gene augmentation would have to occur early in life is LCA due to cone-rod homeobox (CRX) mutations (55). Delivery of the vector is not in itself a barrier, as approaches for performing subretinal injections have been developed in both small and large animal models and in humans and at different stages of maturation of the eye (from gestation through adulthood) (Figure 5C) (56–62). After subretinal injection, only the cells coming in contact with the recombinant viral vectors are transduced – a benefit in terms of preventing transduction to unaffected cells. The volume of injected material determines the area/number of transduced cells. The localized detachment caused by the injection (Figure 5) resolves spontaneously within several hours of the procedure, leaving little residual damage (63, 64).

Gene augmentation therapy in the clinic

To date, the first human gene augmentation studies have involved 18 subjects, all of whom had LCA due to *RPE65* mutations. All 18 of the subjects enrolled were injected once unilaterally with rAAV2 carrying the human *RPE65* cDNA in volumes ranging from 0.15–1.0 ml (60, 61, 63–65). Enrollment was completed in June 2009 in a study at the Children’s Hospital of Philadelphia (CHOP) that involved 12 subjects aged 8–44 years. This study showed that delivery of up to 1.5×10^{11} vector genomes (vg) of rAAV2.h*RPE65*v2 to the subretinal space was safe and efficacious in all 12 individuals. The subjects showed both subjective and objective improvements in retinal and visual function, and the improvements were stable through the latest time point (2.5 years). The extent of recovery was age dependent, with children showing the greatest improvement. The five children in the study are now able to ambulate independently and to participate in normal classroom and athletic endeavors (64). Improvements in retinal/visual function have been stable for at least 2 years following vector administration (64, 65). The studies at University College London and the University of Pennsylvania/University of Florida have so far each enrolled three young adults (60–62). There were no safety concerns in any of the trials, and there was evidence of efficacy, with improvements in light sensitivity noted in some of the subjects in the University of Pennsylvania/University of Florida study and the University College London study. The various trials differ with respect to promoter sequence, the area of the retina targeted, some of the test protocols, and the exact dose



and volume administered. The data to date argue that subretinal gene transfer of rAAV2.*hRPE65* is safe and efficacious and leads to long-term improvements in retinal/visual function.

Building on the first clinical gene augmentation trials

The successes of the first human gene augmentation therapy studies involving patients with LCA caused by mutations in *RPE65* provide the foundation for gene therapy approaches for the treatment of other forms of AR and XL nonsyndromic retinal dystrophies. The primary focus once efficacy is established in animal models concerns the safety of transgene delivery. So far, the risks of toxicity/immune response due to delivery of up to 1.5×10^{11} vg rAAV2 and to exposure of RPE cells to RPE65 protein have been discharged, at least through the 2.5-year time point (64). However, many of the diseases under consideration will require gene transfer to photoreceptors instead of RPE cells, and this will necessitate use of a different vector. Further, some of the transgenes are membrane proteins and are therefore more likely to engender an immune response. Preclinical safety data in large animal models should be predictive of the risks, similar to the situation in LCA-*RPE65* studies (36, 66, 67).

A potential safety concern is posed by the report that AAV capsids can persist in retinal cells long after administration (68). The significance of this finding is unknown, particularly since no inflammation was observed in the animals that were studied. However, it does raise the possibility that delayed or chronic inflammation could evolve. In the study of LCA-*RPE65*, we have found no inflammation in animals followed as long as 10 years after rAAV injection (J. Bennett et al., unpublished observations). Finally, another safety concern is the possibility that rAAV particles could inadvertently target or spread to adjacent cells. The primary concern with respect to diseases in which photoreceptors or RPE cells are the primary cell targets is that rAAV could leak into the vitreous during the subretinal injection procedure and then transduce ganglion cells. This could result in expression in visual pathways in the brain (68–70). So far, however, there have been no reports of CNS toxicity in preclinical or clinical studies using subretinal or intravitreal delivery of rAAV.

The next questions are what diseases are next in line and what are the challenges in developing treatments for the remaining hundreds of inherited forms of retinal degeneration? The subsequent targets will be selected in consideration of the following scientific criteria: first, the targeted disease should lead to significant visual impairment; second, the transgene cassette must meet the cargo requirements for the currently available vectors; third, the selected vectors must target the primary cell population efficiently and stably; fourth, an animal model with a relevant phenotype should be available in which to demonstrate proof of concept; fifth, there should be a sufficient number of patients (more than 25) identified with the given disease so that clinical trials can be carried out; and last, there must be evidence that a sufficient number of cells exists in the patients that could be rejuvenated by gene delivery.

Given the currently available set of reagents, animal models, and knowledge base, there are more than a dozen different immediate potential targets. The design of each of the trials is likely to differ based on the disease characteristics, rate of progression of disease, and ethical issues. Likewise, the outcome measures are likely to differ from target to target, depending on the age of the subjects (and thus their ability to carry out particular test procedures), the nature of the disease, and the rate of disease progression. The final

determinant in the selection of AR and XL retinal dystrophies for gene augmentation studies is the availability of funds to carry out these expensive translational studies.

While costs of proof-of-concept studies can be met by conventional funding mechanisms such as government grants and private foundations, clinical trials are usually not covered by such mechanisms, and the costs of these studies are considerable. The expenses include the generation and validation of the clinical vector, preclinical safety studies, maintaining the appropriate regulatory oversight, and the clinical trial itself. Although the diseases under consideration qualify for “orphan” status (i.e., they affect fewer than 200,000 people in the United States) and there are incentives for developing treatments for such diseases, there are very few large pharmaceutical companies willing to cover clinical trial costs given the small size of the target population. We predict that it would be difficult for a pharmaceutical company to break even let alone make a profit on a rare disease in which a drug is administered only once, unless large fees were to be billed for the drug.

An additional challenge is to determine the appropriate stage of the disease process at which to test the intervention. In many of the diseases, the degenerative component progresses more rapidly than in LCA caused by mutations in *RPE65*. Also, in diseases affecting differentiation of photoreceptors, intervention in infancy might be required to maximize the chance of restoring and preserving vision. Indeed, in most of the patients with LCA, treatment might be optimal in children younger than three years of age due to decreases in the plasticity of the retinal/central nervous system connections after that age. The Recombinant DNA Advisory Committee’s approval of carrying out a gene therapy study of LCA caused by mutations in *RPE65* first in children aged eight years and older (Recombinant DNA Advisory Committee 2005, Discussion of Human Gene Transfer Protocol #0510-740; http://oba.od.nih.gov/rdna/rac_past_meeting_2005_dec_13.html) and then in children ages three years and older (http://oba.od.nih.gov/rdna/rac_past_meeting_2009_webcasts.html#dec09) will pave the way for obtaining approval for enrolling even younger subjects in retinal gene therapy trials. Another important question is whether it is safe to administer vector to the eye contralateral to that treated in the initial clinical trials. All of the subjects in the CHOP LCA-*RPE65* clinical trial have requested treatment of the contralateral eye, as now their uninjected eyes (previously their best-seeing eyes) do not function as well as their injected eyes. The concern about readministration is that the initial injection will serve to immunize the subjects against the AAV2 capsid or the transgenic protein and that the second exposure could serve as a “booster shot” and lead to a harmful immune response. This concern is a theoretical one, as, so far, the measured immune responses in these patients have been benign (63, 64). In addition, readministration of high-dose (1.5×10^{11} vg) rAAV2.*hRPE65*v2 to the contralateral eye in large animals that had previously been immunized with AAV proved safe and efficacious (71). The results of future readministration studies in patients with LCA due to mutations in *RPE65* will be useful in determining the appropriate trial design for new disease targets, particularly with respect to the advisability of injecting both eyes simultaneously in order to minimize the potential immunologic risks of a later readministration.

It is important not to oversell the potential of gene therapy to patients who are considering enrollment in future studies of gene therapy for retinal degeneration. The success of the LCA-*RPE65*



trial situation may be unique in that there was useful vision early in life in most of these patients. In addition, as this disease involves a deficiency of an enzyme, efficiency of transduction and RPE expression may not have to be 100% in order to achieve efficacy. In primary photoreceptor diseases, it will be important to treat the maximum possible number of photoreceptors in a given portion of the retina to maximize improvement in retinal/visual function. It will also be important to regulate the amount of protein photoreceptors produce, as too much may be toxic and too little may not result in benefit. Recent reports involving gene augmentation therapy in animal models of retinal degeneration indicate, however, that rescue of vision is possible even in some of the most severe diseases, such as LCA associated with *AIPL1* mutations (32, 72).

Conclusions

The tremendous progress in delineating the molecular bases of inherited retinal degeneration together with recent reports on the success of gene augmentation therapy for LCA caused by mutations in *RPE65* provide great promise for future applications of genetic therapies to blindness. Many obstacles lie ahead in applying gene therapy to the other potentially more challenging forms of retinal degeneration; however, the tools are available now to tackle a number of these diseases. The ultimate goal is to translate gene-based treatments to clinical practice. To make such treatments routine, there will have to be many changes in the approaches of clinicians to these diseases. Comprehensive, cost-effective screening tools still need to be developed, and clinicians need to offer genotyping tests to their patients. Progress in these ventures is underway. The work to date provides hope for patients with inherited retinal diseases, and in the next decade we believe

that it is likely that novel therapeutic strategies will be developed for a number of these genetic defects.

Acknowledgments

The work of the authors was made possible by the Foundation Fighting Blindness (FFB) USA (BR-GE-0507- 0381-RAD to A.I. den Hollander; CHOP-Penn Center grant and FFB-Wynn grant to J. Bennett), the Foundation for Retinal Research (F.P.M. Cremers, J. Bennett, and A.I. den Hollander), Research to Prevent Blindness (J. Bennett), the Paul and Evanina Mackall Foundation Trust, and the F.M. Kirby Foundation (J. Bennett and A. Black). The following organizations funded research for F.P.M. Cremers and A.I. den Hollander: Henkes Stichting, Research Fonds Oogheelkunde Nijmegen, Stichting Wetenschappelijk Onderzoek Oogziekenhuis, Macula Degeneratie Fonds, Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, F.P. Fischer Stichting, Gelderse Blinden Stichting, Landelijke Stichting voor Blinden en Slechtzienden (LSBS), Stichting Blindenhulp, Stichting Blinden-penning, Stichting Nederlands Oogheelkundig Onderzoek, Stichting Ondersteuning Oogheelkunde's-Gravenhage, and Stichting ter Verbetering van het Lot der Blinden Nederland.

Address correspondence to: Jean Bennett, Department of Ophthalmology, University of Pennsylvania, 309C Stellar-Chance Labs, 422 Curie Blvd, Philadelphia, Pennsylvania 19104, USA. Phone: 215.898.0915; Fax: 215.573.7155; E-mail: jebennet@mail.med.upenn.edu. Or to: Frans P.M. Cremers, Department of Human Genetics, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Phone: 31.24.3614017; Fax: 31.21.3668752; E-mail: F.Cremers@antrg.umcn.nl.

1. Heckenlively J. *Retinitis Pigmentosa*. New York, New York, USA: Lippincott Williams & Wilkins; 1988.
2. den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: genes, proteins and disease mechanisms. *Prog Retin Eye Res*. 2008;27(4):391–419.
3. Blacharski PA. Fundus flavimaculatus. In: Newsome DA, ed. *Retinal Dystrophies And Degenerations*. New York, New York, USA: Raven Press; 1988.
4. Walia S, Fishman GA. Natural history of phenotypic changes in Stargardt macular dystrophy. *Ophthalmic Genet*. 2009;30(2):63–68.
5. Michaelides M, Hunt DM, Moore AT. The cone dysfunction syndromes. *Br J Ophthalmol*. 2004; 88(2):291–297.
6. Thiadens AA, et al. Homozygosity mapping reveals PDE6C mutations in patients with early-onset cone photoreceptor disorders. *Am J Hum Genet*. 2009; 85(2):240–247.
7. Allikmets R, et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. *Nat Genet*. 1997;15(3):236–246.
8. Sharon D, Sandberg MA, Rabe VW, Stillberger M, Dryja TP, Berson EL. RP2 and RPGR mutations and clinical correlations in patients with X-linked retinitis pigmentosa. *Am J Hum Genet*. 2003; 73(5):1131–1146.
9. Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases [published online ahead of print March 31, 2010]. *Prog Retin Eye Res*. doi:10.1016/j.preteyeres.2010.03.004.
10. Cremers FP, et al. Autosomal recessive retinitis pigmentosa and cone-rod dystrophy caused by splice site mutations in the Stargardt's disease gene ABCR. *Hum Mol Genet*. 1998;7(3):355–362.
11. Maugeri A, et al. Mutations in the ABCA4 (ABCR) gene are the major cause of autosomal recessive cone-rod dystrophy. *Am J Hum Genet*. 2000; 67(4):960–966.
12. Wang H, et al. Mutations in SPATA7 cause Leber congenital amaurosis and juvenile retinitis pigmentosa. *Am J Hum Genet*. 2009;84(3):380–387.
13. den Hollander AI, et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. *Am J Hum Genet*. 2006;79(3):556–561.
14. Kohl S, et al. CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia. *Eur J Hum Genet*. 2005;13(3):302–308.
15. Zernant J, et al. Genotyping microarray (disease chip) for Leber congenital amaurosis: detection of modifier alleles. *Invest Ophthalmol Vis Sci*. 2005;46(9):3052–3059.
16. Klevering BJ, et al. Microarray-based mutation analysis of the ABCA4 (ABCR) gene in autosomal recessive cone-rod dystrophy and retinitis pigmentosa. *Eur J Hum Genet*. 2004;12(12):1024–1032.
17. Ng SB, et al. Exome sequencing identifies the cause of a mendelian disorder. *Nat Genet*. 2010;42(1):30–35.
18. Nikopoulos K, et al. Next-generation sequencing of a 40 Mb linkage interval reveals TSPAN12 mutations in patients with familial exudative vitreoretinopathy. *Am J Hum Genet*. 2010;86(2):240–247.
19. Abd El-Aziz MM, et al. EYS, encoding an ortholog of Drosophila spacemark, is mutated in autosomal recessive retinitis pigmentosa. *Nat Genet*. 2008; 40(11):1285–1287.
20. Chang B, et al. Mouse models of ocular diseases. *Vis Neurosci*. 2005;22(5):587–593.
21. Narfstrom K, Wrigstad A, Nilsson S. The Briard dogs: a new animal model of congenital stationary night blindness. *Br J Ophthalmol*. 1989;73(9):750–756.
22. Semple-Rowland S, Lee N, Van Hooser J, Palczewski K, Baehr W. A null mutation in the photoreceptor guanylate cyclase gene causes the retinal degeneration chicken phenotype. *Proc Natl Acad Sci USA*. 1998;95(3):1271–1276.
23. Williams ML, et al. Lentiviral expression of retinal guanylate cyclase-1 (RetGC1) restores vision in an avian model of childhood blindness. *PLoS Med*. 2006;3(6):e201.
24. Naik R, Mukhopadhyay A, Ganguli M. Gene delivery to the retina: focus on non-viral approaches. *Drug Discov Today*. 2009;14(5–6):306–315.
25. Bainbridge JW, Tan MH, Ali RR. Gene therapy progress and prospects: the eye. *Gene Ther*. 2006; 13(16):1191–1197.
26. Cai X, Conley SM, Nash Z, Fliesler SJ, Cooper MJ, Naash MI. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. *FASEB J*. 2010;24(4):1178–1191.
27. Vandenberghe LH, Wilson JM, Gao G. Tailoring the AAV vector capsid for gene therapy. *Gene Ther*. 2009;16(3):311–319.
28. Zhong L, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. *Proc Natl Acad Sci USA*. 2008;105(22):7827–7832.
29. Bennett J, Duan D, Engelhardt JF, Maguire AM. Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction. *Invest Ophthalmol Vis Sci*. 1997;38(13):2857–2863.
30. Lebherz C, Maguire A, Tang W, Bennett J, Wilson JM. Novel AAV serotypes for improved ocular gene transfer. *J Gene Med*. 2008;10(4):375–382.
31. Allocca M, et al. Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. *J Virol*. 2007;81(20):11372–11380.
32. Tan MH, et al. Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete *Aipl1* deficiency using



AAV2/2 and AAV2/8 vectors. *Hum Mol Genet*. 2009; 18(12):2099–2114.

33. McCarty DM. Self-complementary AAV vectors; advances and applications. *Mol Ther*. 2008; 16(10):1648–1656.

34. Acland GM, et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. *Mol Ther*. 2005;12(6):1072–1082.

35. McCarty DM, Young SM Jr, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. *Annu Rev Genet*. 2004;38:819–845.

36. Bennicelli J, et al. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. *Mol Ther*. 2008;16(3):458–465.

37. Smith AJ, Schlichtenbrede FC, Tschner M, Bainbridge JW, Thrasher AJ, Ali RR. AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. *Mol Ther*. 2003;8(2):188–195.

38. Auricchio A, et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. *Hum Mol Genet*. 2001;10(26):3075–3081.

39. Von Seggern DJ, et al. In vivo transduction of photoreceptors or ciliary body by intravitreal injection of pseudotyped adenoviral vectors. *Mol Ther*. 2003;7(1):27–34.

40. Kong J, et al. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. *Gene Ther*. 2008;15(19):1311–1320.

41. Kumar-Singh R, Yamashita CK, Tran K, Farber DB. Construction of encapsidated (gutted) adenovirus minichromosomes and their application to rescue of photoreceptor degeneration. *Methods Enzymol*. 2000;316:724–743.

42. Pauwels K, et al. State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations. *Curr Gene Ther*. 2009;9(6):459–474.

43. Hoffman LM, Maguire AM, Bennett J. Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery. *Invest Ophthalmol Vis Sci*. 1997;38(11):2224–2233.

44. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. *J Virol*. 1998;72(2):926–933.

45. Yang Y, Su Q, Wilson JM. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. *J Virol*. 1996;70(10):7209–7212.

46. Raper S, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. *Mol Genet Metab*. 2003;80(1–2):148–158.

47. Bennett J. Immune response following intraocular delivery of recombinant viral vectors. *Gene Therapy*. 2003;10(11):977–982.

48. Dong JY, Fan PD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. *Hum Gene Ther*. 1996;7(17):2101–2112.

49. Allocca M, et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. *J Clin Invest*. 2008;118(S):1955–1964.

50. Dong B, Nakai H, Xiao W. Characterization of genome integrity for oversized recombinant AAV vector. *Mol Ther*. 2010;18(1):87–92.

51. Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. *Mol Ther*. 2010;18(1):80–86.

52. van Deutekom JC, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. *Hum Mol Genet*. 2001; 10(15):1547–1554.

53. Reich SJ, et al. Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. *Hum Gene Ther*. 2003; 14(1):37–44.

54. Yang J, Zhou W, Zhang Y, Zidon T, Ritchie T, Engelhardt JF. Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. *J Virol*. 1999;73(11):9468–9477.

55. Walia S, et al. Visual acuity in patients with Leber's congenital amaurosis and early childhood-onset retinitis pigmentosa. *Ophthalmology*. 2010; 117(6):1190–1198.

56. Bennett J, et al. Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. *Nat Med*. 1996;2(6):649–654.

57. Acland GM, et al. Gene therapy restores vision in a canine model of childhood blindness. *Nat Genet*. 2001;28(1):92–95.

58. Bennett J, et al. Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. *Proc Natl Acad Sci U S A*. 1999;96(17):9920–9925.

59. Dejneka NS, et al. In utero gene therapy rescues vision in a murine model of congenital blindness. *Mol Ther*. 2004;9(2):182–188.

60. Cideciyan AV, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. *Proc Natl Acad Sci U S A*. 2008;105(39):15112–15117.

61. Bainbridge JW, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. *N Engl J Med*. 2008;358(21):2231–2239.

62. Cideciyan AV, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at one year. *Hum Gene Ther*. 2009;20(9):999–1004.

63. Maguire AM, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. *N Engl J Med*. 2008;358(21):2240–2248.

64. Maguire AM, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. *Lancet*. 2009; 374(9701):1597–1605.

65. Simonelli F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. *Mol Ther*. 2010; 18(3):643–650.

66. Jacobson SG, et al. Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. *Mol Ther*. 2006;13(6):1074–1084.

67. Jacobson SG, et al. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. *Hum Gene Ther*. 2006;17(8):845–858.

68. Stieger K, et al. Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates. *Mol Ther*. 2009;17(3):516–523.

69. Dudus L, et al. Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. *Vision Res*. 1999;39(15):2545–2553.

70. Guy J, Qi X, Muzychka N, Hauswirth WW. Reporter expression persists 1 year after adeno-associated virus-mediated gene transfer to the optic nerve. *Arch Ophthalmol*. 1999;117(7):929–937.

71. Amado D, et al. Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. *Sci Transl Med*. 2010; 2(21):21r16.

72. Sun X, et al. Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. *Gene Ther*. 2010; 17(1):117–131.

73. Weng J, et al. Insights into the function of rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. *Cell*. 1999;98(1):13–23.

74. Weskamp G, et al. Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. *Mol Cell Biol*. 2002;22(5):1537–1544.

75. Dyer MA, et al. Retinal degeneration in Aipl1-deficient mice: a new genetic model of Leber congenital amaurosis. *Brain Res Mol Brain Res*. 2004;132(2):208–220.

76. Liu X, et al. AIPL1, the protein that is defective in Leber congenital amaurosis, is essential for the biosynthesis of retinal rod cGMP phosphodiesterase. *Proc Natl Acad Sci U S A*. 2004;101(38):13903–13908.

77. Ramamurthy V, Niemi GA, Reh TA, Hurley JB. Leber congenital amaurosis linked to AIPL1: a mouse model reveals destabilization of cGMP phosphodiesterase. *Proc Natl Acad Sci U S A*. 2004; 101(38):13897–13902.

78. Wycisk KA, et al. Structural and functional abnormalities of retinal ribbon synapses due to Cacna2d4 mutation. *Invest Ophthalmol Vis Sci*. 2006; 47(8):3523–3530.

79. Chang B, et al. In-frame deletion in a novel centrosomal/ciliary protein CEP290/NPHP6 perturbs its interaction with RPGR and results in early-onset retinal degeneration in the rd16 mouse. *Hum Mol Genet*. 2006;15(11):1847–1857.

80. Menotti-Raymond M, et al. Mutation in CEP290 discovered for cat model of human retinal degeneration. *J Hered*. 2007;98(3):211–220.

81. Graf C, Niwa S, Muller M, Kinzel B, Bornancin F. Wild-type levels of ceramide and ceramide-1-phosphate in the retina of ceramide kinase-like-deficient mice. *Biochem Biophys Res Commun*. 2008; 373(1):159–163.

82. Biel M, et al. Selective loss of cone function in mice lacking the cyclic nucleotide-gated channel CNG3. *Proc Natl Acad Sci U S A*. 1999;96(13):7553–7557.

83. Huttel S, et al. Impaired channel targeting and retinal degeneration in mice lacking the cyclic nucleotide-gated channel subunit CNGB1. *J Neurosci*. 2005; 25(1):130–138.

84. Zhang Y, et al. Knockout of GARP and the beta-subunit of the rod cGMP-gated channel disrupts disk morphogenesis and rod outer segment structural integrity. *J Cell Sci*. 2009;122(pt 8):1192–1200.

85. Sidjanin DJ, et al. Canine CNGB3 mutations establish cone degeneration as orthologous to the human achromatopsia locus ACHM3. *Hum Mol Genet*. 2002;11(16):1823–1833.

86. Ding XQ, Harry CS, Umino Y, Matveev AV, Fliesler SJ, Barlow RB. Impaired cone function and cone degeneration resulting from CNGB3 deficiency: down-regulation of CNGA3 biosynthesis as a potential mechanism. *Hum Mol Genet*. 2009; 18(24):4770–4780.

87. Komaromy AM, et al. Targeting gene expression to cones with human cone opsin promoters in recombinant AAV. *Gene Ther*. 2008;15(14):1049–1055.

88. Mehalow AK, et al. CRB1 is essential for external limiting membrane integrity and photoreceptor morphogenesis in the mammalian retina. *Hum Mol Genet*. 2003;12(17):2179–2189.

89. van de Pavert SA, et al. Crumbs homologue 1 is required for maintenance of photoreceptor cell polarization and adhesion during light exposure. *J Cell Sci*. 2004;117(pt 18):4169–4177.

90. van de Pavert SA, et al. A single amino acid substitution (Cys249Trp) in Crb1 causes retinal degeneration and deregulates expression of pituitary tumor transforming gene Pttg1. *J Neurosci*. 2007; 27(3):564–573.

91. Furukawa T, Morrow EM, Cepko CL. Crx, a novel otx-like homeobox gene, shows photoreceptor-specific expression and regulates photoreceptor differentiation. *Cell*. 1997;91(4):531–541.

92. Chang B, et al. Cone photoreceptor function loss-3, a novel mouse model of achromatopsia due to a mutation in Gnat2. *Invest Ophthalmol Vis Sci*. 2006; 47(11):5017–5021.

93. Alexander JJ, et al. Restoration of cone vision in a mouse model of achromatopsia. *Nat Med*. 2007; 13(6):685–687.

94. Semple-Rowland SL, Lee NR, Van Hooser JP, Palczewski K, Baehr W. A null mutation in the photo-



receptor guanylate cyclase gene causes the retinal degeneration chicken phenotype. *Proc Natl Acad Sci U S A*. 1998;95(3):1271–1276.

95. Yang RB, Robinson SW, Xiong WH, Yau KW, Birch DG, Garbers DL. Disruption of a retinal guanylyl cyclase gene leads to cone-specific dystrophy and paradoxical rod behavior. *J Neurosci*. 1999;19(14):5889–5897.

96. Haire SE, et al. Light-driven cone arrestin translocation in cones of postnatal guanylate cyclase-1 knockout mouse retina treated with AAV-GC1. *Invest Ophthalmol Vis Sci*. 2006;47(9):3745–3753.

97. Petersen-Jones SM, Entz DD, Sargent DR. cGMP phosphodiesterase-alpha mutation causes progressive retinal atrophy in the Cardigan Welsh corgi dog. *Invest Ophthalmol Vis Sci*. 1999;40(8):1637–1644.

98. Sakamoto K, McCluskey M, Wensel TG, Naggert JK, Nishina PM. New mouse models for recessive retinitis pigmentosa caused by mutations in the Pde6a gene. *Hum Mol Genet*. 2009;18(1):178–192.

99. Suber ML, et al. Irish setter dogs affected with rod/cone dysplasia contain a nonsense mutation in the rod cGMP phosphodiesterase beta-subunit gene. *Proc Natl Acad Sci U S A*. 1993;90(9):3968–3972.

100. Chang B, et al. Two mouse retinal degenerations caused by missense mutations in the beta-subunit of rod cGMP phosphodiesterase gene. *Vision Res*. 2007;47(5):624–633.

101. Dekomien G, Runte M, Godde R, Eppelen JT. Generalized progressive retinal atrophy of Sloughi dogs is due to an 8-bp insertion in exon 21 of the PDE6B gene. *Cytogenet Cell Genet*. 2000;90(3–4):261–267.

102. Chang B, et al. A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked to mutations in the PDE6C gene. *Proc Natl Acad Sci U S A*. 2009;106(46):19581–19586.

103. Zangerl B, et al. Identical mutation in a novel retinal gene causes progressive rod-cone degeneration in dogs and retinitis pigmentosa in humans. *Genomics*. 2006;88(5):551–563.

104. Maeda A, et al. Retinol dehydrogenase (RDH12) protects photoreceptors from light-induced degeneration in mice. *J Biol Chem*. 2006;281(49):37697–37704.

105. Zacchigna S, et al. Loss of the cholesterol-binding protein prominin-1/CD133 causes disk morphogenesis and photoreceptor degeneration. *J Neurosci*. 2009;29(7):2297–2308.

106. Vollrath D, et al. Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk. *Proc Natl Acad Sci U S A*. 2001;98(22):12584–12589.

107. Tschner M, et al. Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapy. *Gene Ther*. 2005;12(8):694–701.

108. Liou GI, et al. Early onset photoreceptor abnormalities induced by targeted disruption of the interphotoreceptor retinoid-binding protein gene. *J Neurosci*. 1998;18(12):4511–4520.

109. Chang B, Heckenlively JR, Hawes NL, Roderick TH. New mouse primary retinal degeneration (rd-3). *Genomics*. 1993;16(1):45–49.

110. Kurth I, et al. Targeted disruption of the murine retinal dehydrogenase gene Rdh12 does not limit visual cycle function. *Mol Cell Biol*. 2007;27(4):1370–1379.

111. Driessens CA, et al. Disruption of the 11-cis-retinol dehydrogenase gene leads to accumulation of cis-retinols and cis-retinyl esters. *Mol Cell Biol*. 2000;20(12):4275–4287.

112. Shang E, et al. Targeted disruption of the mouse cis-retinol dehydrogenase gene: visual and nonvisual functions. *J Lipid Res*. 2002;43(4):590–597.

113. Andrieu-Soler C, et al. Single-stranded oligonucleotide-mediated in vivo gene repair in the rd1 retina. *Mol Vis*. 2007;13:692–706.

114. Davis RJ, et al. Functional rescue of degenerating photoreceptors in mice homozygous for a hypomorphic cGMP phosphodiesterase 6 b allele (Pde6bH620Q). *Invest Ophthalmol Vis Sci*. 2008;49(11):5067–5076.

115. Pang JJ, et al. AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEbeta mutation. *Invest Ophthalmol Vis Sci*. 2008;49(10):4278–4283.

116. Souied EH, Reid SN, Piri NI, Lerner LE, Nusinowitz S, Farber DB. Non-invasive gene transfer by iontophoresis for therapy of an inherited retinal degeneration. *Exp Eye Res*. 2008;87(3):168–175.

117. Lem J, et al. Morphological, physiological, and biochemical changes in rhodopsin knockout mice. *Proc Natl Acad Sci U S A*. 1999;96(2):736–741.

118. Humphries MM, et al. Retinopathy induced in mice by targeted disruption of the rhodopsin gene. *Nat Genet*. 1997;15(2):216–219.

119. Chen P, et al. A photic visual cycle of rhodopsin regeneration is dependent on Rgr. *Nat Genet*. 2001;28(3):256–260.

120. Pinto LH, et al. Generation, characterization, and molecular cloning of the Noerg-1 mutation of rhodopsin in the mouse. *Vis Neurosci*. 2005;22(5):619–629.

121. Wang Z, Wen XH, Ablonczy Z, Crouch RK, Makino CL, Lem J. Enhanced shutoff of phototransduction in transgenic mice expressing palmitoylation-deficient rhodopsin. *J Biol Chem*. 2005;280(26):24293–24300.

122. Saari JC, et al. Visual cycle impairment in cellular retinaldehyde binding protein (CRALBP) knockout mice results in delayed dark adaptation. *Neuron*. 2001;29(3):739–748.

123. Gao J, et al. Progressive photoreceptor degeneration, outer segment dysplasia, and rhodopsin mislocalization in mice with targeted disruption of the retinitis pigmentosa-1 (Rp1) gene. *Proc Natl Acad Sci U S A*. 2002;99(8):5698–5703.

124. Liu Q, Lyubarsky A, Skalet JH, Pugh EN, Pierce EA. Rp1 is required for the correct stacking of outer segment discs. *Invest Ophthalmol Vis Sci*. 2003;44(10):4171–4183.

125. Narfstrom K. Retinal dystrophy or ‘congenital stationary night blindness’ in the Briard dog. *Vet Ophthalmol*. 1999;2(1):75–76.

126. Aguirre GD, Baldwin V, Pearce-Kelling S, Narfstrom K, Ray K, Acland GM. Congenital stationary night blindness in the dog: common mutation in the RPE65 gene indicates founder effect. *Mol Vis*. 1998;4:23.

127. Redmond TM, et al. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. *Nat Genet*. 1998;20(4):344–351.

128. Pang JJ, et al. Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA). *Mol Vis*. 2005;11:152–162.

129. Hong DH, Pawlyk BS, Shang J, Sandberg MA, Bereson EL, Li T. A retinoid pigmentosa GTPase regulator (RPGR)-deficient mouse model for X-linked retinitis pigmentosa (RP3). *Proc Natl Acad Sci U S A*. 2000;97(7):3649–3654.

130. Zhang Q, et al. Different RPGR exon ORF15 mutations in Canids provide insights into photoreceptor cell degeneration. *Hum Mol Genet*. 2002;11(9):993–1003.

131. Zhao Y, et al. The retinitis pigmentosa GTPase regulator (RPGR)-interacting protein: subserving RPGR function and participating in disk morphogenesis. *Proc Natl Acad Sci U S A*. 2003;100(7):3965–3970.

132. Mellersh CS, et al. Canine RPGRIP1 mutation establishes cone-rod dystrophy in miniature longhaired dachshunds as a homologue of human Leber congenital amaurosis. *Genomics*. 2006;88(3):293–301.

133. Palfi A, et al. Adeno-associated virus-mediated rhodopsin replacement provides therapeutic benefit in mice with a targeted disruption of the rhodopsin gene. *Hum Gene Ther*. 2010;21(3):311–323.

134. Hagstrom SA, Duyao M, North MA, Li T. Retinal degeneration in *tulp1*^{-/-} mice: vesicular accumulation in the interphotoreceptor matrix. *Invest Ophthalmol Vis Sci*. 1999;40(12):2795–2802.

135. Ikeda S, et al. Retinal degeneration but not obesity is observed in null mutants of the tubby-like protein 1 gene. *Hum Mol Genet*. 2000;9(2):155–163.

136. Pieke-Dahl S, Ohlemiller KK, McGee J, Walsh EJ, Kimberling WJ. Hearing loss in the RBF/DnJ mouse, a proposed animal model of Usher syndrome type IIa. *Hear Res*. 1997;112(1–2):1–12.

137. Liu X, et al. Usherin is required for maintenance of retinal photoreceptors and normal development of cochlear hair cells. *Proc Natl Acad Sci U S A*. 2007;104(11):4413–4418.

138. Pang JJ, et al. Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. *Mol Ther*. 2006;13(3):565–572.

139. Aguirre GK, et al. Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation. *PLoS Med*. 2007;4(6):e230.

140. Bemelmans AP, et al. Lentiviral gene transfer-mediated cone vision restoration in RPE65 knockout mice. *Adv Exp Med Biol*. 2008;613:89–95.

141. Pawlyk BS, et al. Gene replacement therapy rescues photoreceptor degeneration in a murine model of Leber congenital amaurosis lacking RPGRIP. *Invest Ophthalmol Vis Sci*. 2005;46(9):3039–3045.